Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
Michael BaslerElmer MauritsGerjan de BruinJulia KoernerHerman S OverkleeftMarcus GroettrupPublished in: British journal of pharmacology (2017)
This study with a novel pan-immunoproteasome inhibitor substantiates that the immunoproteasome is a promising drug target for the treatment of inflammatory diseases and that exclusive inhibition of LMP7 is not necessary for therapeutic effectiveness. Our results will promote the design of new generations of immunoproteasome inhibitors with optimal therapeutic efficacy for clinical use in the treatment of autoimmunity and cancer.